The STUDIA UNIVERSITATIS BABEŞ-BOLYAI issue article summary

The summary of the selected article appears at the bottom of the page. In order to get back to the contents of the issue this article belongs to you have to access the link from the title. In order to see all the articles of the archive which have as author/co-author one of the authors mentioned below, you have to access the link from the author's name.

  
       
         
    STUDIA CHEMIA - Issue no. 2 / 2015  
         
  Article:   IMMUNOMODULATORY POTENTIAL OF PALLADIUM(II) COMPLEXES WITH (1E,6E)-1,7-BIS (3,4-DIMETHOXYPHENYL) HEPTA-1,6-DIENE-3,5-DIONE.

Authors:  . 		 
       
         
  Abstract:   In the cancer chemotherapy the metal-based cytotoxic drugs are invariable components of therapeutic protocols, despite the biologic drugs expansion. A current tendency is to design metal-based drugs with highest efficacy and limited toxicity on normal human cells implicated in immune response. Therefore we synthesized and characterized two palladium(II) complexes with (1E,6E)-1,7-bis(3,4-dimethoxypenyl)hepta-1,6-diene-3,5-dione, a curcuminoid like ligand; their cytotoxicity towards tumor cells was tested, and their expected impact on T and B lymphocytes was measured in vitro. The lymphocytes treatment with the free ligand, and with the two complexes 1 and 2, increased significantly the proportion of the T helper CD4 positive cell population, concomitant with the decrease of T effector CD8 positive cells. The B cells were not affected by 1, but 2 has a minor inhibitory effect on CD19 and CD45RA cells. The cells function was tested through the compounds modulator effect on membrane markers CD25 and GITR, both being slightly down regulated by 2, compensating of CD4 overexpression and CD8 down regulation. Moreover, complex 1 displayed minimal interferences with the cellular antitumor immunity, acting as a selective inhibitor of cancer cells growth.

Keywords: (1E,6E)-1,7-bis(3,4-dimethoxyphenyl)hepta-1,6-diene-3,5-dione, palladium complex, cancer therapy, immune response
 
         
     
         
         
      Back to previous page